Entera Bio Ltd. (NASDAQ:ENTX) has scheduled a conference call for 19th November 2020 at 8:30 AM Eastern Time to announce its 3Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.enterabio.com
To participate on the live call, please dial (855) 547-3865 U.S. or (409) 217-8787 (International), with passcode : 9495026
Earnings Expectation
Entera Bio Ltd. is expected to report third quarter earnings results, before market open, on Thursday 19th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.2 per share from revenue of $ 0.00 million. Looking ahead, the full year loss are expected at $ 0.68 per share on the revenues of $ 0.09 million.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The companys lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules.
